The short version
- A recent investigation found that many high-priced menopause supplements contain insufficient levels of essential nutrients compared to standard multivitamins.
- The global market for these products is expanding rapidly, yet experts argue the pricing and marketing strategies exploit consumer health anxieties without providing proven benefits.
- Regulators are facing criticism for failing to curb misleading claims, while industry representatives maintain that supplements can address specific nutritional needs during life transitions.
A comprehensive analysis by the consumer advocacy group Which? has challenged the value proposition of the booming menopause supplement market. The investigation reveals that products costing hundreds of pounds annually often provide no greater benefit than inexpensive, standard multivitamins. This finding comes as the global industry for menopausal health aids is projected to grow significantly, reaching an estimated $25 billion by 2030 from a current valuation of nearly $17 billion.
The core issue identified by researchers is not necessarily the presence of ingredients, but their quantity and relevance. Many popular supplements aimed at women over 45 lack meaningful concentrations of key nutrients required during perimenopause and menopause. Specifically, calcium and vitamin D are critical for maintaining bone health as estrogen levels decline. However, the study found that numerous products either omitted these vital components entirely or included them in doses too low to be physiologically beneficial.
The financial disparity between specialized supplements and general alternatives is stark. Which? examined 26 popular products sold by major retailers including Holland & Barrett, Boots, and Amazon. The analysis showed that a high-quality multivitamin, such as Asda’s A-Z Multivitamins, costs approximately £22 per year and contains all essential vitamins along with significant amounts of calcium and magnesium. In contrast, specialized menopause blends can cost more than 15 times that amount while offering inferior nutritional profiles.
Specific examples highlight the gap between marketing claims and actual content. Love Mushrooms’ Empower supplement, which costs £485 annually for a two-tablet daily dose, was found to lack menopause-specific nutrients like magnesium and calcium entirely. Similarly, Wild Nutrition’s Women’s 45+ Daily Multi Nutrient, priced at £468 per year, contained significantly lower levels of vitamin D, calcium, and magnesium than recommended by the National Health Service. Even the highest-scoring product in the study, Vitabiotics’ Menopace Max, cost £340 a year, far exceeding the price of basic alternatives.
These findings align with broader academic research into the sector. A separate study by University College London (UCL) analyzed 201 supplements sold in the UK and discovered that less than half contained adequate vitamin D and calcium. Furthermore, the majority of ingredients used in these products were not specifically recommended by major menopause societies. This suggests a systemic issue where product formulation is driven more by market trends than by established medical guidelines.
Public health experts have expressed strong concern regarding the regulatory environment surrounding these products. Shefalee Loth, a public health nutritionist at Which?, described the industry as a 'wild west' where regulators have failed to control dubious marketing and unchecked quasi-medical claims. The argument is that companies are capitalizing on health anxiety and insecurities among women seeking relief from symptoms such as hot flushes, poor sleep, and mood swings.
Dr. Xand van Tulleken, an honorary associate professor at the UCL Institute for Global Health, emphasized the disparity in resource allocation. He noted that annual spending on menopause supplements dwarfs investment in actual menopause research by hundreds of times. According to Dr. van Tulleken, there is no persuasive evidence that these supplements significantly alleviate symptoms, and some may even be dangerous. He characterized the pricing and marketing strategies as exploitative, describing them as a massive rip-off for consumers who are desperate to improve their well-being.
Despite these criticisms, industry representatives defend the role of supplementation. Martin Last, director general of the Health Food Manufacturers’ Association, stated that manufacturers encourage adherence to food regulations. He argued that life stages such as menopause can create increased nutritional demands that may be met through supplementation as an addition to a healthy diet. However, the recent findings suggest that many consumers are paying premium prices for products that do not meet these specific needs effectively.
The implications of this research extend beyond individual consumer choices. As the market continues to expand, the lack of stringent oversight poses challenges for public health. Women navigating menopause may be spending substantial sums on products that offer little more than a basic multivitamin. Until regulatory frameworks tighten and marketing claims are held to higher evidentiary standards, consumers remain vulnerable to misleading information in a rapidly growing sector.
Moving forward, the focus will likely shift toward greater transparency and stricter enforcement of labeling laws. Health professionals may need to play a larger role in guiding patients toward cost-effective and evidence-based nutritional strategies. For now, the data suggests that a simple, affordable multivitamin remains a more reliable option for maintaining general health during menopause than many of the specialized products currently flooding the market.
Sources behind this briefing
Go to the original reporting
- The Guardian World↗Menopause supplements costing more than £400 a year ‘no better than cheap multivitamin’
